Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
Updated results of a phase II trial of brentuximab vedotin combined with R-CHOP in frontline treatment of patients (pts) with high-intermediate/high-risk diffuse large B-cell lymphoma (DLBCL). Bartlett, N. L., Farber, C. M., Yasenchak, C. A., Ansell, S., Advani, R. H., Knapp, M. H., Fayad, L., Kolibaba, K. S., Patel-Donnelly, D., Seetharam, M., Yimer, H., Manley, T., Burke, J. M., Holkova, B., Budde, L., Halwani, A. AMER SOC CLINICAL ONCOLOGY. 2015
View details for Web of Science ID 000358036901819